Can a Low-Dose drug delay menopause? new trial aims to find out

NCT ID NCT05836025

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether low-dose rapamycin can slow ovarian aging in 50 women aged 35-45 who are in early perimenopause. Participants take 5mg of rapamycin or a placebo weekly for 12 weeks. Researchers will measure hormone levels and ovarian reserve to see if the drug delays age-related decline.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Rapamycin (low dose, 5mg/week for 12 weeks)

What this could lead to

If it works, this could point toward a way to slow ovarian aging and extend fertility in perimenopausal women.

What could go wrong

This is a small, early-phase pilot study with only 50 participants. Results may not apply to all women, and the effect on fertility is not directly tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIMENOPAUSAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

    New York, New York, 10032, United States